Stoffel et al. identified that eczema and Pso arising in patients with inflammatory bowel disease and rheumatoid arthritis undergoing TNF inhibitor therapy exhibit unique immunological profiles compared to conventional forms of atopic eczema and psoriasis [24]. Here, TNF is linked to inflammatory bowel disease.